



Rapid Dose Therapeutics Press Release

BURLINGTON, ONTARIO, CANADA, June 18, 2021 /EINPresswire.com/ -- Rapid Dose Announces Delayed Filing of its Annual Financial Disclosure

Rapid Dose Therapeutics Corp. (the "Company") (CSE: DOSE) announces that the filing of its annual financial statements for the year ended February 28, 2021, including related management discussion and analysis, and CEO and CFO certifications (collectively, the "Annual Financial Filings") will be delayed beyond the filing deadline of June 28, 2021 (the "Filing Deadline"). The Annual Financial Filings will not be filed by the Filing Deadline due principally to delays resulting from the work associated with the audit of the Issuer's amalgamation with 2544737 Ontario Limited, operating as Consolidated Craft Brands, announced by the Issuer on March 8, 2021, and delays resulting from COVID 19 operating protocols observed by the Company and its auditor.

The Company is working on the steps required to complete the Annual Financial Filings and expects to be able to file the Annual Financial Filings by August 31, 2021. The Company will provide updates as further information relating to the Annual Financial Filings becomes available.

The Company has applied to the applicable securities regulatory authorities for a management cease trade order ("MCTO") to be imposed against the Chief Executive Officer and Chief Financial Officer of the Company precluding them from trading securities of the Company until the Annual Financial Filings are filed. The MCTO would not affect the ability of shareholders who are not insiders of the Company to trade their securities. There is no certainty that the MCTO will be granted. If the MCTO is not granted, the applicable securities regulatory authorities could issue a general cease trade order against the Company

for failure to file the Annual Filings by the Filing Deadline.

Until the Annual Financial Filings are filed, the Company intends to satisfy the provisions of the alternative information guidelines under National Policy 12-203 - Management Cease Trade Orders by issuing bi-weekly default status reports. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed

MARK A UPSDELL

Rapid Dose Therapeutics Corp.

+1 647-200-4709

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/544207393>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.